189 results on '"Kee, Damien"'
Search Results
2. The Fight Tumour Blindness Registry: Efficient capture of high-quality real-world data in uveal melanoma
3. Patient Experience of Complex Genomic Sequencing Exploring Patient Preference, Barriers, and Enablers for Delivery
4. Positron Emission Tomography/Computed Tomography Transformation of Oncology: Melanoma and Skin Malignancies
5. Targeting homologous recombination deficiency in uterine leiomyosarcoma
6. Teaching Cases in Nuclear Oncology: Malignant Melanoma
7. Diagnostic Applications of Nuclear Medicine: Malignant Melanoma
8. EWSR1-BEND2 fusion defines an epigenetically distinct subtype of astroblastoma
9. RAF1 rearrangements are common in pancreatic acinar cell carcinomas
10. What matters most to people with metastatic uveal melanoma? A qualitative study to inform future measurement of health-related quality of life
11. FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment
12. Rheumatic immune-related adverse events secondary to anti–programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series
13. Potentially actionable FGFR2 high-level amplification in thymic sebaceous carcinoma
14. Durable response to combination immunotherapy using nivolumab and ipilimumab in metastatic succinate dehydrogenase (SDH)-deficient gastrointestinal stroma tumour
15. A Matched Molecular and Clinical Analysis of the Epithelioid Haemangioendothelioma Cohort in the Stafford Fox Rare Cancer Program and Contextual Literature Review
16. Clinical and radiological evolution of cerebral amyloid angiopathy-related inflammation in the context of anti-PD-1 immunotherapy
17. Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature
18. Supplementary Tables from Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma
19. Table S1 from Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers
20. Authorship change form from Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers
21. Additional file 1 of Targeting homologous recombination deficiency in uterine leiomyosarcoma
22. Is there a role for combined anti–PD‐1/CTLA‐4 checkpoint blockade in the management of advanced biliary tract cancers?
23. Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study
24. Targeted Therapies for Cutaneous Melanoma
25. Cerebellar Augmented Joint Control for a Humanoid Robot
26. Distributed Control of Gait for a Humanoid Robot
27. Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma.
28. Two years of the Australian Rare Cancer Portal: a national referral service for rare cancer information and research.
29. The psychosocial impact of the Australian Rare Cancer Portal on patients with rare cancer.
30. Molecular therapy selection in treatment-refractory advanced cancers: A retrospective cohort study determining the utility of TOPOGRAPH knowledge base.
31. Contributors
32. Optimal Selection of Targeted Therapies for Melanoma Patients
33. Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
34. EWSR1-BEND2 fusion defines an epigenetically distinct subtype of astroblastoma
35. Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial
36. Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
37. Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma
38. Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy
39. WhiMSICAL : A global Waldenström's Macroglobulinemia patient‐derived data registry capturing treatment and quality of life outcomes
40. RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
41. Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538
42. CART-WHEEL.org: An Ethically Approved Online Database for Patient-Entered Data to Facilitate Rare Cancer Research
43. Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers
44. Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers
45. Evaluating barriers to uptake of comprehensive genomic profiling (CGP) in advanced cancer patients (pts).
46. Combination immunotherapy with ipilimumab and nivolumab in patients with advanced biliary tract cancers.
47. NOMINATOR: Feasibility of genomic testing of rare cancers to match cancer to treatment.
48. Combination immunotherapy with ipilimumab and nivolumab in patients with rare gynaecological malignancies.
49. FDG-PET metabolic tumor volume in advanced melanoma treated with ipilimumab and nivolumab (ipi/nivo).
50. Cerebellar Augmented Joint Control for a Humanoid Robot
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.